https://doi.org/10.4081/hmr.v2i14.510

Prolonging time to progression and survival in relapsed/refractory multiple myeloma

Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006
Published: June 10, 2009
Abstract Views: 183
PDF: 386
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Pieter Sonneveld
support@pagepress.org
Each year, over 16,500 new cases of multiple myeloma (MM) are diagnosed in the USA alone, making it the second most common type of haematological malignancy after non-Hodgkin’s lymphoma.1 Current treatment options for MM are non-curative, and the 5-year survival rate for all patients with MM has improved only slightly over the last 20−25 years, from 25% to 32%.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Sonneveld, P. (2009). Prolonging time to progression and survival in relapsed/refractory multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.510
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).